PI3K inhibitor improves PFS in BELLE-2 trial. Cancer Discov. 2016 ; 6 : 115-6.
Krop IE, Mayer IA, Ganju V, et al. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI) : a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016 ; 17 : 811-21.
Dickler MN, Saura C, Richards DA, et al. A phase II study of the PI3K inhibitor taselisib (GDC-0032) combined with fulvestrant (F) in patients (pts) with HER2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer (BC) [abstract]. J Clin Oncol. 2016 ; 34 Suppl : 520.